164 related articles for article (PubMed ID: 31606199)
1. Proteomic analysis of the papillary thyroid microcarcinoma.
Jin S; Bao W; Yang YT; Fu Q; Bai Y; Liu Y
Ann Endocrinol (Paris); 2019 Nov; 80(5-6):293-300. PubMed ID: 31606199
[TBL] [Abstract][Full Text] [Related]
2. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
4. Papillary thyroid microcarcinomas that metastasize to lymph nodes.
Dirikoc A; Tam AA; Ince N; Ozdemir D; Topaloglu O; Alkan A; Yazgan AK; Ersoy R; Cakir B
Am J Otolaryngol; 2021; 42(5):103023. PubMed ID: 33838358
[TBL] [Abstract][Full Text] [Related]
5. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
7. Risk factors for lymph node metastasis (LNM) in patients with papillary thyroid microcarcinoma (PTMC): role of preoperative ultrasound.
Zhao C; Jiang W; Gao Y; Niu W; Zhang X; Xin L
J Int Med Res; 2017 Jun; 45(3):1221-1230. PubMed ID: 28534700
[TBL] [Abstract][Full Text] [Related]
8. Preoperative predictors of lateral neck lymph node metastasis in papillary thyroid microcarcinoma.
Liu Z; Lei J; Liu Y; Fan Y; Wang X; Lu X
Medicine (Baltimore); 2017 Mar; 96(10):e6240. PubMed ID: 28272218
[TBL] [Abstract][Full Text] [Related]
9. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
[TBL] [Abstract][Full Text] [Related]
10. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma.
Yuan J; Li J; Chen X; Lin X; Du J; Zhao G; Chen Z; Wu Z
Bull Cancer; 2017 Jun; 104(6):516-523. PubMed ID: 28476312
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution.
Xu Y; Xu L; Wang J
J Surg Res; 2018 Jan; 221():128-134. PubMed ID: 29229118
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma.
Park JP; Roh JL; Lee JH; Baek JH; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Am J Surg; 2014 Sep; 208(3):412-8. PubMed ID: 24602323
[TBL] [Abstract][Full Text] [Related]
13. Nodal metastasis and recurrence in papillary thyroid microcarcinoma.
Pisanu A; Saba A; Podda M; Reccia I; Uccheddu A
Endocrine; 2015 Mar; 48(2):575-81. PubMed ID: 25007850
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic reticulum aminopeptidase 2 is highly expressed in papillary thyroid microcarcinoma with cervical lymph node metastasis.
Kim WY; Lee JB; Kim HY; Woo SU; Son GS; Bae JW
J Cancer Res Ther; 2015; 11(2):443-6. PubMed ID: 26148615
[TBL] [Abstract][Full Text] [Related]
15. Peripheral location and infiltrative margin predict invasive features of papillary thyroid microcarcinoma.
Lee WK; Lee J; Kim H; Lee SG; Choi SH; Jeong S; Kwon HJ; Jung SG; Jo YS
Eur J Endocrinol; 2019 Aug; 181(2):139-149. PubMed ID: 31146263
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors.
Zheng W; Wang X; Rui Z; Wang Y; Meng Z; Wang R
Nucl Med Commun; 2019 May; 40(5):477-483. PubMed ID: 30973839
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of risk factors for central lymph node metastasis in papillary thyroid microcarcinoma].
Wang ZH; Zhang YJ; Fu GM; Chen YB
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):12-17. PubMed ID: 30704163
[No Abstract] [Full Text] [Related]
18. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections.
So YK; Son YI; Hong SD; Seo MY; Baek CH; Jeong HS; Chung MK
Surgery; 2010 Sep; 148(3):526-31. PubMed ID: 20189620
[TBL] [Abstract][Full Text] [Related]
19. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
20. Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases.
Zhi J; Zhao J; Gao M; Pan Y; Wu J; Li Y; Li D; Yu Y; Zheng X
Int J Clin Oncol; 2018 Feb; 23(1):59-65. PubMed ID: 28744725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
